MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma

"Multi-Antigen Stimulated Cell Therapy-I Injection (MASCT-I) is a sequential immune cell therapy.~Camrelizumab is an immune checkpoint inhibitors against PD-1.~Apatinib is a highly selective tyrosine kinase inhibitor targeting VEGFR2."